BioSpace News Archive

Business

Bluebird Pins Hopes on Zynteglo Uptake, FDA Verdict Amid Cash Constraints

The biotech company is looking to forge a path to profitability by scaling up the commercial uptake of Zynteglo and winning the FDA’s approval for its lovo-cel gene therapy for sickle cell disease.

August 9, 2023
·
2 min read
·
Tristan Manalac
Business

Takeda, Denali Scrap Phase I Alzheimer’s Drug Showing ‘Narrow Therapeutic Window’

The companies partnered to develop the antibody transport vehicle in late 2021, but will continue their 2018 agreement to pursue other drugs in preclinical development.

August 9, 2023
·
2 min read
·
Connor Lynch
Deals

Regeneron Buys Decibel’s Hearing Loss Gene Therapies in $109M Deal

The acquisition will bring gene therapy company Decibel Therapeutics into Regeneron’s fold after a six-year partnership, targeting different forms of congenital and monogenic hearing loss.

August 9, 2023
·
2 min read
·
Connor Lynch
Business

Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS

Following an FDA approval and a Phase III flop, Mirati CEO David Meek has resigned in a “mutually agreed” decision, the company announced late Tuesday as it searches for a permanent replacement.

August 9, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Novartis Scores Phase III Chronic Hives Wins as Sanofi Challenges

Late-stage data from two studies showed Novartis’ BTK inhibitor remibrutinib improves symptoms of chronic spontaneous urticaria. The company will file for regulatory approval in 2024.

August 9, 2023
·
2 min read
·
Kate Goodwin
Drug Development

The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch

With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.

August 9, 2023
·
11 min read
·
Heather McKenzie
Business

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2023.

August 9, 2023
·
12 min read
Business

ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, announced its second quarter 2023 financial results and provided a business update.

August 9, 2023
·
20 min read
Genetown

Merus N.V. Announces Proposed Public Offering of Common Shares - August 09, 2023

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the launch of a proposed underwritten public offering of its common shares.

August 9, 2023
·
10 min read
Drug Development

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc.® announced Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine -cooperative inhibitor evaluated in methylthioadenosine phosphorylase deleted cancers.

August 9, 2023
·
7 min read